Åsa Jellverts disputation

Fredagen den 5 november 2021 kl 09:00 avlägger Åsa Jellvert, leg läkare vid Kirurgkliniken, NÄL medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs universitet

Plats: Arvid Carlsson, Medicinaregatan 3, Akademicum
Tid: Fredagen den 5 november 2021 kl 09:00
Fakultetsopponent: Professor Jan Oldenburg, Akershus Universitetssykehus, Oslo, Norge

Avhandlingen baseras på följande delarbeten

I. Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer
Jellvert Å, Åhs D, Olausson J, Lissbrant IF, Damber JE, Welén K.
ACTA Oncologica 2018; 557: 895-901
II. Biomarkers for prediction of response and survival of chemotherapy in patients with advanced prostate cancer.
Jellvert Å, Larsson K, Schnedl L, Damber JE, Gasi Tandefelt D* Welén K*.
Manuscript
III. Progression-free survival advantage of docetaxel plus bicalutamide versus bicalutamide alone for non-metastatic prostate cancer, a Scandinavian Prostate Cancer Group Study, SPCG-14.
Josefsson A, Jellvert Å, Holmberg E, Brasso K, Meidahl Petersen P, Aaltomaa S, Luukkaa M, Verhagen P, de Wit R, Ahlgren G, André O, Castellanos E, Seke M, Widmark A, Turesson I, Damber JE.
Manuscrip